In last trading session, Olema Pharmaceuticals Inc (NASDAQ:OLMA) saw 0.61 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $4.41 trading at $0.04 or 0.92% at ring of the bell on the day assigns it a market valuation of $301.35M. That closing price of OLMA’s stock is at a discount of -276.87% from its 52-week high price of $16.62 and is indicating a premium of 10.43% from its 52-week low price of $3.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.79 million shares which gives us an average trading volume of 1.07 million if we extend that period to 3-months.
For Olema Pharmaceuticals Inc (OLMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.17 in the current quarter.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Upright in the green during last session for gaining 0.92%, in the last five days OLMA remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $4.41 price level, adding 4.75% to its value on the day. Olema Pharmaceuticals Inc’s shares saw a change of -24.36% in year-to-date performance and have moved -4.34% in past 5-day. Olema Pharmaceuticals Inc (NASDAQ:OLMA) showed a performance of -10.73% in past 30-days. Number of shares sold short was 8.47 million shares which calculate 8.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 83.67% to its current value. Analysts have been projecting 27 as a low price target for the stock while placing it at a high target of 27. It follows that stock’s current price would drop -512.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -512.24% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -105.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -7.49% while estimates for its earnings growth in next 5 years are of -13.34%.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
Insiders are in possession of 3.21% of company’s total shares while institution are holding 101.58 percent of that, with stock having share float percentage of 104.95%. Investors also watch the number of corporate investors in a company very closely, which is 101.58% institutions for Olema Pharmaceuticals Inc that are currently holding shares of the company. BVF INC/IL is the top institutional holder at OLMA for having 9.14 million shares of worth $98.85 million. And as of 2024-06-30, it was holding 16.2322 of the company’s outstanding shares.
The second largest institutional holder is PARADIGM BIOCAPITAL ADVISORS LP, which was holding about 7.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 14.0428 of outstanding shares, having a total worth of $85.52 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.63 shares of worth $7.19 million or 2.20% of the total outstanding shares. The later fund manager was in possession of 1.07 shares on Dec 31, 2024 , making its stake of worth around $4.72 million in the company or a holder of 1.44% of company’s stock.
